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he ADP ribosylation factor (ARF) GTP binding proteins
are believed to mediate cytoskeletal remodeling and
vesicular trafﬁcking along the secretory pathway.
Here we show that ARF6 is speciﬁcally associated with
dense-core secretory granules in neuroendocrine PC12 cells.
Stimulation with a secretagogue triggers the recruitment of
secretory granules to the cell periphery and the concomitant
activation of ARF6 by the plasma membrane-associated
guanine nucleotide exchange factor, ARF nucleotide binding
site opener (ARNO). Expression of the constitutively inactive
ARF6(T27N) mutant inhibits secretagogue-dependent exo-
cytosis from PC12 cells. Using a mutant of ARF6 speciﬁcally
T
 
impaired for PLD1 stimulation, we ﬁnd that ARF6 is func-
tionally linked to phospholipase D (PLD)1 in the exocytotic
machinery. Finally, we show that ARNO, ARF6, and PLD1
colocalize at sites of exocytosis, and we demonstrate direct
interaction between ARF6 and PLD1 in stimulated cells.
Together, these results provide the ﬁrst direct evidence
that  ARF6 plays a role in calcium-regulated exocytosis in
neuroendocrine cells, and suggest that ARF6-stimulated
PLD1 activation at the plasma membrane and consequent
changes in membrane phospholipid composition are critical
for formation of the exocytotic fusion pore.
 
Introduction
 
Calcium-triggered release of hormones and peptides from
neuroendocrine cells is mediated by the fusion of large,
dense-core secretory granules with the plasma membrane, a
spatially and temporally controlled process based on a com-
plex network of interactions between regulatory molecules
and mechanical components. Cytoskeletal rearrangements
are a prerequisite for exocytosis. Actin filaments form a
cortical network that separates secretory granules into a
small release-ready granule pool and a larger reserve pool,
subjecting the transit of granules to the plasma membrane
to a carefully orchestrated regulation (Trifaro et al., 2000).
Classically viewed as a barrier that hinders the movement
of reserve granules to the plasma membrane (Aunis and
Bader, 1988), it is now believed that the actin cortex provides
also tracks along which the granules are pulled to the sites
of exocytosis (Lang et al., 2000). Once docked at the
plasma membrane, granules undergo membrane fusion
through a mechanism governed by SNAREs (Jahn and
Südhof, 1999; Chen and Scheller, 2001). The role of the
membrane lipid composition at the site of fusion is less
well understood, but several reports suggest that lipids are
essential partners for proteins in the basic fusion machinery
(Schmidt et al., 1999; Weigert et al., 1999; Vitale et al.,
2001). A specific feature of the exocytotic release in secretory
cells is its tight regulation, as the speed, length, and number
of exocytotic events must be controlled. Thus, additional
proteins able to link and coordinate the successive recruit-
ment, docking, and fusion steps into the integrated secretion
machinery are necessarily required but most of them remain
to be identified.
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ADP ribosylation factor (ARF)* GTPases play important
roles in membrane trafficking events (Moss and Vaughan,
1998; Donaldson and Jackson, 2000). ARF6, the most
structurally divergent member of the family (Chavrier and
Goud, 1999), is found exclusively at the plasma and/or en-
dosomal membranes in various cells types (Peters et al.,
1995; Cavenagh et al., 1996). The protein has been pro-
posed to play a role in cell motility (Song et al., 1998; Santy
and Casanova, 2001), vesicle recycling at the plasma mem-
brane (Radhakrishna and Donaldson, 1997; D’Souza-Scho-
rey et al., 1998), Fc-mediated phagocytosis (Zhang et al.,
1999a) and insulin-regulated secretion (Yang and Muekler,
1999), and Glut-4 translocation (Millar et al., 1999). Taken
together, these findings suggest that ARF6 is an ubiquitous
regulator of vesicle transport at the plasma membrane.
ARF6 is unique among the six mammalian ARFs in its
ability to stimulate cortical actin rearrangements (Rad-
hakrishna et al., 1999; Boshans et al., 2000). Because
ARF6 also activates phospholipase D (PLD; Massenburg et
al., 1994), a lipid-modifying enzyme recently described as a
key factor for exocytosis in neurons and neuroendocrine
cells (Humeau et al., 2001; Vitale et al., 2001), it would be
attractive to hypothesize that ARF6 functions by coordinat-
ing reorganization of the actin cytoskeleton with the lipid
modifications required for neuronal exocytosis. We demon-
strate here that ARF6 is the sole member of the ARF family
able to exert direct control on the exocytotic machinery. We
show that ARF6 is in its inactive GDP-bound state when as-
sociated with secretory granules but then switches to its ac-
tive GTP-bound state at the plasma membrane upon cell
stimulation. Our results indicate that the guanine nucleo-
tide exchange factor, ARF nucleotide binding site opener
(ARNO), is a regulator of ARF6 functions in this setting. Fi-
nally, we show that ARF6 participates in the regulation of
secretion, most likely through the direct activation of PLD1
at the site of exocytosis.
 
Results
 
Secretagogue-evoked stimulation activates ARF6 
at the plasma membrane
 
To probe the role of ARF proteins in dense-core granule
exocytosis, we first investigated their intracellular distribu-
tion. The relatively low level of endogenous ARFs and the
difficulty of generating antibodies able to discriminate be-
tween the six members of the ARF family (which share
 
 
 
70% identity), prompted us instead to visualize them us-
ing overexpression of epitope-tagged isoforms. PC12 cells
were cotransfected with an HA-tagged representative of each
ARF class and with growth hormone (GH) to visualize
dense-core secretory granules (Caumont et al., 2000; Vitale
et al., 2001). ARF1, ARF3, and ARF5 are concentrated in
the perinuclear region (Fig. 1), which contains the Golgi
as identified with the pECFP-Golgi marker (unpublished
data). Neither ARF1, ARF3, nor ARF5 colocalized with the
GH-labeled secretory granules distributed in the rest of the
 
cytoplasm (Fig. 1). In contrast, ARF6 colocalized both with
GH (Fig. 1) and GFP–chromogranin A (unpublished data)
throughout the cell, indicating that it represents most likely
the sole ARF protein associated with mature secretory gran-
ules in PC12 cells.
We then compared the distribution of overexpressed WT
and mutant ARF6 in resting and stimulated PC12 cells us-
ing in addition anti-SNAP25 antibodies to visualize the
plasma membrane. In resting cells, WT ARF6, the inactive
ARF6(T27N) mutant unable to bind GTP, and the consti-
tutively active ARF6(Q67L) mutant unable to hydrolyze
GTP (Peters et al., 1995) associated with GH-containing
secretory granules (Fig. 2). Membrane depolarization by
high potassium concentrations initiates calcium-dependent
exocytosis in PC12 cells. Accordingly, a 5-min stimulation
with 59 mM K
 
 
 
 triggered a partial movement of secretory
granules to the cell periphery and the docking of a portion of
the granules at the plasma membrane, as indicated by the in-
creased colocalization of GH with SNAP-25 (Fig. 2, mask
GH/SNAP-25). WT and mutant ARF6 displayed a staining
pattern very similar to GH in K
 
 
 
-treated cells, indicating
that ARF6 accompanied the secretory granules to the periph-
ery (Fig. 2, mask ARF6/SNAP-25). Immunoelectron mi-
croscopy confirmed the association of ARF6 with the plasma
 
*Abbreviations used in this paper: ARF, ADP ribosylation factor;
ARNO, ARF nucleotide binding site opener; GH, growth hormone; PA,
phosphatidic acid; PLD, phospholipase D.
Figure 1. Subcellular localization of overexpressed ARF1, ARF3, 
ARF5, and ARF6 in PC12 cells. PC12 cells cotransfected with GH 
and the indicated HA-tagged ARF constructs were stained with 
either monoclonal anti-HA antibodies (for ARF1, ARF3, and ARF5) 
or rabbit anti-ARF6 antibodies. Rabbit or monoclonal anti-GH 
antibodies were used to stain secretory granules in transfected cells. 
Bars, 5  m. 
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membrane after stimulation with elevated K
 
 
 
 (Fig. 3). ARF6
was detected not only on secretory granules within the cyto-
plasm and on granules docked at the plasma membrane, but
also on portions of the plasma membrane seemingly free of
granules. However, coated pits and vesicles were not deco-
rated by gold particles, suggesting that ARF6 does not un-
dergo clathrin-dependent endocytosis in this cell type.
To correlate the intracellular distribution of ARF6 with its
nucleotide status, we used a biochemical approach that in
the first phase offers an alternative method to probe ARF6
subcellular distribution: PC12 cells expressing WT or mu-
tated ARF6 were incubated with [
 
32
 
P]orthophosphate to la-
bel the ARF6-bound nucleotide, subjected to subcellular
fractionation, and assayed for ARF6 distribution using im-
munoprecipitation and quantitation of the coprecipitated la-
beled nucleotide. As illustrated in Fig. 4 B, the labeled nu-
cleotide was not recovered from the cytosol, signifying, as
expected, that ARF6 is membrane associated. Instead, under
resting conditions, most of the labeled guanine nucleotides
were immunoprecipitated from the secretory granule frac-
tions (Fig. 4 B), in agreement with the granule association of
ARF6 observed by confocal and electron microscopy. How-
ever, stimulation with elevated K
 
 
 
 increased the amount of
labeled guanine nucleotides detected in the plasma mem-
brane fraction at the expense of the granule fraction (Fig. 4
B), consistent with the immunofluorescent results shown in
Fig. 2 and the Western blot results in Fig. 4 A. This redistri-
bution was exaggerated by ARF6(Q67L) and blunted by
ARF6(T27N). Note that endogenous ARF6 similarly trans-
located from secretory granules to the plasma membrane
upon cell stimulation (Fig. 4 A). The observation of ARF6
at the plasma membrane in stimulated cells could result
from the fusion of granules into the plasma membrane at the
sites of exocytosis. In support of this hypothesis, dopamine–
 
 
 
-hydroxylase, a granule membrane protein, could be de-
tected in the plasma membrane-containing fraction when
the membrane fractions were prepared from stimulated cells
(Fig. 4 A). However, note the low level of GH in this frac-
tion (Fig. 4 A), suggesting that most of the granule mem-
brane recovered with the plasma membrane originated from
granules that had already released their content. ARF6 could
also directly interact with a plasma membrane–bound pro-
tein after granule docking, and thereby be retained at the
plasma membrane upon cell fractionation.
In a second phase, this method permits the nucleotide sta-
tus of ARF6 in resting and stimulated cells to be assessed by
analyzing on chromatography plates the guanine nucleotides
bound to the immunoprecipitated WT and mutant ARFs.
As shown in Fig. 5, in resting cells, only GDP was found to
be associated with the ARF6 on secretory granules, and this
was true even for ARF6(Q67L) which exhibits a dramatic
preference for GTP. Some ARF6(Q67L) was also detected
on the plasma membrane in resting cells (Fig. 4 B), but it
was found to be loaded both with GDP and GTP (Fig. 5).
Stimulation with K
 
 
 
 triggered a partial translocation of the
ARF6s to the plasma membrane, but only WT ARF6 and
ARF6(Q67L) switched to their active GTP-bound state.
97% of the ARF6(T27N) remained in the GDP-bound
state despite its association with the plasma membrane (Fig.
5). Taken together, these results indicate that the secretory
granule–associated ARF6 protein is in its inactive GDP-
bound form. Stimulation with a secretagogue triggers the ac-
tivation of ARF6 but the GDP to GTP exchange occurs
only at or after arrival to the plasma membrane.
 
ARNO activates ARF6 at the plasma membrane 
in stimulated PC12 cells
 
In chromaffin cells, ARNO, a nucleotide exchange factor for
ARF proteins (Chardin et al., 1996; Frank et al., 1998b), is
localized at the plasma membrane (Caumont et al., 2000).
Figure 2. Distribution of WT and 
mutated ARF6 proteins in resting and 
stimulated PC12 cells. PC12 cells were 
transfected with pXS-ARF6, pXS-
ARF6(T27N), or pXS-ARF6(Q67L) in 
combination with the GH expression 
plasmid. 48 h after transfection, cells 
were stimulated for 5 min with 59 mM 
K
  (S) or maintained under resting 
conditions (R) and then processed for 
immunocytochemistry. Cells were 
stained with monoclonal anti-GH and 
rabbit polyclonal anti-ARF6 antibodies, 
postfixed, and then stained with 
monoclonal anti-SNAP25 antibodies. 
Confocal images were recorded in the 
same optical section by a triple exposure 
procedure. Masks representing the 
regions of colocalization (ARF6/SNAP-25 
or GH/SNAP-25) were generated by 
selecting the double-labeled pixels. 
Bars, 5  m. 
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To establish whether ARNO is the activator of ARF6 at the
cell surface in stimulated PC12 cells, we compared the intra-
cellular distribution of ARNO and ARF6. In resting PC12
cells, ARF6 associates with secretory granules as described
earlier, whereas ARNO is restricted to the plasmalemma
(Fig. 6 A). In contrast, in K
 
 
 
-stimulated cells, ARF6 colocal-
ized with ARNO at the plasma membrane (Fig. 6 A). To in-
vestigate directly whether ARNO triggers nucleotide ex-
change on the plasma membrane–associated ARF6, we
determined the nature of the guanine nucleotide bound
to immunoprecipitated ARF6 in cells cotransfected with
ARNO or the catalytically inactive ARNO(E156K) mutant
that lacks nucleotide exchange activity (Frank et al., 1998a).
Overexpression of ARNO or ARNO(E156K) modified nei-
ther the level of expression of ARF6 (unpublished data) nor
its subcellular distribution in resting and stimulated PC12
cells (Fig. 6 B, top); as was shown earlier, ARF6 was detected
exclusively in the fraction containing secretory granules and
it was in its GDP-bound state (Fig. 6 B, bottom). Stimula-
tion with potassium triggered ARF6 translocation to the
plasma membrane to a similar extent in all of the cells (Fig. 6
B). However, in cells overexpressing ARNO, all of the
plasma membrane–associated ARF6 was in its GTP-bound
state, whereas in cells expressing ARNO(E156K) the plasma
membrane–bound ARF6 remained in its GDP-bound form
(Fig. 6 B). Thus, ARNO stimulates GDP/GTP exchange on
ARF6 in PC12 cells. Critically, overexpression of ARNO did
not induce GTP loading of the secretory granule-associated
ARF6 in resting or stimulated cells, indicating that ARNO
can activate ARF6 only at or near the plasma membrane.
Figure 3. Ultrastructural immunolocalization of HA-ARF6 in 
resting and stimulated PC12 cells. PC12 cells expressing HA-ARF6 
were maintained in Locke’s solution (A) or stimulated with 59 mM 
K
  (B–G), fixed, and stained with anti-HA antibodies. In stimulated 
cells, silver-intensified immunogold particles concentrate at the 
plasma membrane (compare A and B, arrowheads). Immunogold 
particles label the membrane plasma (C), the periphery of the 
secretory granules present in the cytoplasm (D), the docking site 
of secretory granules with the plasma membrane (E), and omega 
structures found at the plasma membrane most likely corresponding 
to granules having released their content (F). Coated pits at the 
plasma membrane and intracellular coated vesicles (G, arrows) are 
devoid of HA-ARF6 immunogold labeling. N, nucleus; asterisk, 
nontransfected cell; arrowheads in A–C, plasma membrane. 
Bars, 250 nm.
Figure 4. Subcellular distribution of radiolabeled HA-ARF6 
proteins in resting and stimulated PC12 cells. PC12 cells expressing 
HA-ARF6, HA-ARF6(T27N), or HA-ARF6(Q67L) were transferred 
to phosphate- and serum-free medium containing 175  Ci 
[
32P]orthophosphate for 24 h. Cells were washed twice and then 
stimulated with 59 mM K
  (Stimulated) or maintained in Locke’s 
solution (Resting) for 15 min. Cells were immediately lysed and 
processed for subcellular fractionation on sucrose gradients. 
Fractions containing endosomes (Endo), cytosol (Cy), plasma 
membrane (PM), and secretory granules (Gr) were collected. 
(A) Fractions were separated by gel electrophoresis and transferred 
to nitrocellulose for immunoblotting analysis using anti-GH (granule 
content), anti-dopamine- -hydroxylase (D H; granule membrane), 
anti–SNAP-25 (plasma membrane), anti-Rab5 (endosomes), and 
anti-HA antibodies. Endogenous ARF6 was detected in parallel 
fractions prepared from nontransfected PC12 cells using anti-ARF6 
antibodies. (B) HA-tagged ARF6 proteins were immunoprecipitated 
from the indicated fractions and labeled guanine nucleotides bound 
to the HA-ARF6 proteins were counted. Similar results were 
obtained from three different cell preparations. 
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ARF6 is a functional element of the exocytotic 
machinery in PC12 cells
 
To establish whether ARF6 plays a role in exocytosis, we ex-
amined the effect of overexpressing the various ARF iso-
forms using GH as a secretory reporter in PC12 cells (Vitale
et al., 2001). As illustrated in Fig. 1, overexpression of
ARF1, ARF3, ARF5, or ARF6 did not apparently modify
the distribution of GH. However, expression of the consti-
tutively active ARF1(Q71L) and ARF3(Q71L) proteins and
the dominant-negative ARF1(T31N) and ARF3(T31N)
slightly but significantly reduced the total cellular GH mea-
sured by radioimmunoassay (Fig. 7 B), in agreement with
the participation of ARF1 and ARF3 in the biosynthetic
pathway of secretory granules (Peters et al., 1995). Of the
ARFs tested, only ARF6 mutants modified the GH secretion
in response to elevated K
 
 
 
 (Fig. 7 C). Expression of the inac-
tive ARF6(T27N) strongly inhibited GH secretion, whereas
ARF6(Q67L) significantly stimulated it (Fig. 7 C). The de-
gree of inhibition observed is consistent with other studies
using this assay to characterize molecular components of
regulated exocytosis (Holz et al., 1994; Sugita et al., 1999).
It is also noteworthy that expression of the catalytically inac-
tive ARNO(E156K) mutant resulted in a comparable inhi-
bition of K
 
 
 
-evoked GH secretion in PC12 cells (Caumont
et al., 2000), most likely because ARNO(E156K) forms an
abortive ternary complex with endogenous ARF6 in which
GDP remains bound to the nucleotide binding site (Béraud-
Dufour et al., 1998).
To confirm that ARF6 plays a role in the exocytotic ma-
chinery, we examined the effect of the ARF6 mutants on
exocytotic activity as visualized by the binding of fluorescent
annexin 5 to patches of phosphatidylserine exposed on the
cell surface by secretory granule fusion (Demo et al., 1998;
Vitale et al., 2001). Resting PC12 cells showed no fluores-
cent annexin 5 patches (Fig. 7 D), indicating that the an-
nexin 5 binding assay does not detect baseline activity in the
absence of secretagogue. Stimulation with elevated K
 
 
 
 trig-
gered the appearance of a patchy pattern of surface annexin
5 binding in cells expressing ARF6 or ARF6(Q67L), but not
in cells expressing the inactive ARF6(T27N) mutant (Fig. 7
D). In line with the finding that ARF6(T27N) inhibits GH
secretion from PC12 cells, this observation suggests that ac-
tivation of ARF6 is critically important for calcium-evoked
exocytosis of dense-core secretory granules.
Figure 5. Nucleotide status of ARF6 in resting and stimulated 
PC12 cells. PC12 cells expressing HA-ARF6 or HA-ARF6 mutants 
were labeled with [
32P]orthophosphate and then incubated in Locke 
(R) or 59 mM K
  (S) for 15 min. Cells were processed for subcellular 
fractionation and HA-tagged ARF6 proteins were immunoprecipitated 
from the cytosol (Cy), plasma membrane (PM), and secretory 
granules (Gr). (Top) 5  l aliquots were analyzed by electrophoresis 
and Western blotting using anti-ARF6 antibodies. (Bottom) Guanine 
nucleotides eluted from the HA-immunoprecipitated ARF6 proteins 
were separated on chromatography plates and subjected to 
autoradiography. Similar results were obtained from three different 
cell preparations.
Figure 6. ARF6 is activated by ARNO at the plasma membrane in 
stimulated PC12 cells. (A) PC12 cells transfected with pXS-ARF6 in 
combination with the pCB7-myc-ARNO expression plasmid were 
incubated in Locke (R) or stimulated with 59 mM K
  (S) for 5 min. 
After fixation, cells were stained with monoclonal anti-myc (ARNO) 
and rabbit polyclonal anti-ARF6 antibodies. In the merge images, 
the yellow-orange staining indicates the areas of colocalization 
between ARNO and ARF6. Bars, 5  m. (B) PC12 cells transfected 
with pXS-ARF6 in combination with pCB7, pCB7-myc-ARNO, or 
pCB7-myc-ARNO(E156K) were labeled with [
32P]orthophosphate 
and then incubated in Locke (Resting) or stimulated with 59 mM K
  
(Stimulated). Cells were subsequently processed for subcellular 
fractionation and HA-ARF6 was immunoprecipitated from the 
cytosol (Cy), the plasma membrane (PM), and the secretory granules 
(Gr). (Top) 5  l aliquots were analyzed by Western blotting using 
anti-ARF6 antibodies. (Bottom) guanine nucleotides bound to 
HA-ARF6 were analyzed by chromatography. Identical results were 
obtained with two independent cell preparations. 
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PLD1 is a molecular partner of ARF6 
in the exocytotic machinery
 
ARF proteins including ARF6 are established activators of
PLD. In neurons and neuroendocrine cells, we previously de-
scribed that a plasma membrane–associated PLD1 plays an im-
portant function in a late postdocking step of exocytosis (Hu-
meau et al., 2001; Vitale et al., 2001). In order to test whether
PLD1 might be an effector of ARF6 in the exocytotic process,
we generated a mutant of ARF6 unable to stimulate PLD ac-
tivity, namely ARF6(N48I), based on analogy with a simi-
lar mutant generated for ARF1 by Jones et al. (1999). As
illustrated in Fig. 8 A, GTP
 
 
 
S binding to recombinant
myrARF6(N48I) was indistinguishable from that of WT
myrARF6. Dissociation of GDP
 
 
 
S from myrARF6(N48I)
and myrARF6 was also very similar (unpublished data).
ARNO stimulated GTP
 
 
 
S binding to myrARF6(N48I) and
to myrARF6 to a similar extent (Fig. 8 A). Additionally, GIT1,
a GAP protein for ARF6 (Vitale et al., 2000a), stimulated GTP
hydrolysis on myrARF6(N48I) (Fig. 8 B). Together, these ex-
periments indicate that the N48I mutation does not affect the
activation/inactivation cycle of ARF6 and its regulation by en-
dogenous accessory proteins. We next tested the ability of
myrARF6(N48I) to stimulate known ARF effectors. In pres-
ence of GTP, cholera toxin ADP-ribosyltransferase activity was
stimulated similarly by myrARF6(N48I) and myrARF6 (Fig. 8
C). However, as intended, the mutation N48I abolished al-
most completely the ability of ARF6 to stimulate PLD1 (Fig. 8
D), making ARF6(N48I) an ideal tool to test the involvement
of the ARF6-PLD pathway in a cellular function.
We next examined whether ARF6 and PLD1 colocalize,
and could thereby physically interact in stimulated PC12
cells. In agreement with the presence of endogenous PLD1
at the plasma membrane in chromaffin cells (Vitale et al.,
2001), GFP-PLD1 was found at the plasma membrane in
both resting and stimulated PC12 cells (Fig. 9 A). Little
ARF6 colocalized with PLD1 in resting cells. In contrast,
stimulation with K
 
 
 
 triggered the colocalization of a fraction
of ARF6 with GFP-PLD1 at the plasma membrane (Fig. 9
Figure 7. ARF6 plays a role in dense-core 
granule exocytosis in PC12 cells. PC12 cells were 
cotransfected with GH and the indicated HA-tagged 
ARF6 constructs. (A) 48 h after transfection, the 
expressed ARF proteins were detected by Western 
blots using anti-HA antibodies. (B) The total GH 
content in cells expressing WT ARFs, constitutively 
inactive ARFs(T/N), or active ARFs(Q/L) was 
measured by radioimmunoassay. In control 
experiments with the empty pXS vector, the GH 
content per well was 5.21 ng   0.12. (C) Transfected 
cells were incubated for 10 min in calcium-free 
Locke’s solution or in 59 mM K
  solution. The net 
K
 -evoked GH release was obtained by subtracting 
the basal release from the release measured in the 
presence of 59 mM K
 . In the different condition 
tested, basal release ranged from 5.2 to 7.1%. The 
net K
 -evoked GH release from cells transfected 
with empty pXS was 24.8%   0.4. Data are given 
as the mean values   SE (n   3). Similar results 
were obtained in three independent experiments 
performed with different cell cultures. (D) PC12 
cells expressing ARF6, ARF6(T27N), or ARF6(Q67L) 
were stimulated with 59 mM K
  in the presence of 
FITC-conjugated annexin 5 (Ax5) to reveal exocytotic 
activity. Cells were subsequently fixed and stained 
with rabbit anti-ARF6 antibodies. The arrow points 
to a nontransfected cell displaying exocytotic 
patches in response to 59 mM K
  while the 
adjacent transfected cell expressing ARF6(T27N) 
exhibits no exocytotic activity. Bars, 5  m. 
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A), thereby making feasible a potential interaction of ARF6
with PLD1 near the site of exocytosis. Direct interaction of
ARF6 and PLD1 in secretagogue-activated cells was assessed
by immunoprecipitation. As illustrated in Fig. 9 B, immu-
noprecipitation of WT ARF6 or the active ARF6(Q67L),
but not the inactive ARF6(T27N), coprecipitated PLD1
from lysates of K
 
 
 
-stimulated PC12 cell but not from lysates
of resting cells (Fig. 9 B), confirming the binding of acti-
vated ARF6 to PLD1 upon cell activation.
Next we examined the effects of ARF6(N48I) and ARF6
(N48I/Q67L) on K
 
 
 
-evoked GH secretion. ARF6(N48I) ex-
pressed in PC12 cells associated with secretory granules (Fig.
10 A) and, similar to WT ARF6, became activated at the
plasma membrane upon cell stimulation (Fig. 10 B). However,
as shown in Fig. 10 C, expression of ARF6(N48I) in PC12
cells clearly decreased GH secretion by 
 
 
 
50%. Furthermore,
superimposing the N48I mutation onto the constitutively ac-
tive ARF6(Q67L) caused it to lose its ability to stimulate exo-
cytosis; instead, ARF6(N48I/Q67L) behaved as a dominant
negative, inhibiting secretion to an extent similar to the PLD1
nonstimulating ARF6(N48I) mutant (Fig. 10 C) and the inac-
tive GDP-bound ARF6(T27N) mutant (Fig. 7 C). Immuno-
precipitation experiments indicate that ARF6(N48I) still binds
to PLD1 upon cell stimulation (unpublished data), suggesting
that the inhibition of secretion after ARF6(N48I) expression is
likely to be due to the partial sequestration and inactivation of
endogenous PLD1. These results argue for a major contribu-
tion of PLD1 in the pathway by which ARF6 regulates exocy-
tosis in neuroendocrine cells.
 
Discussion
 
ARF proteins have been proposed as ubiquitous regulators
of vesicle transport within cells. Here, we investigated their
possible function in calcium-regulated exocytosis of dense-
core secretory granules, using PC12 cells which have proved
to be a good model for the study of neuroendocrine secre-
tion. We find that ARF6 is the sole member of the ARF
family specifically associated with secretory granules and that
it is activated upon secretagogue-evoked stimulation, most
likely after targeting and docking of granules onto the
plasma membrane. Transfection experiments with ARF6
mutants confirm the importance of ARF6 in the exocytotic
reaction in PC12 cells. Our results suggest an intimate con-
nection between ARF6 and the plasma membrane-bound
PLD1 that we recently described as a key factor in the late
fusion reaction in neurons (Humeau et al., 2001) and neu-
roendocrine cells (Vitale et al., 2001).
Figure 8. Characterization of the PLD1-nonresponsive 
ARF6(N48I) mutant. (A) GTP S binding to 0.5  g myrARF6 (circles) 
or myrARF6(N48I) (squares) was estimated for the indicated periods 
of time in the absence (open symbols) or in the presence (closed 
symbols) of 0.5  g ARNO. (B) 0.5  g myrARF6 or myrARF6(N48I) 
with [ -
32P]GTP bound were incubated for 10 min with buffer 
(control) or 250 ng GIT1 before separation of the bound nucleotide 
by TLC. (C) 1  g myrARF6 or myrARF6(N48I) together with 100  M 
of GDP or GTP were incubated with components needed for 
cholera toxin A subunit-catalyzed ADP-ribosylagmatine formation 
for 1 h Basal activity in the absence of guanine nucleotide has been 
subtracted. (D) The activity exhibited by partially purified recombinant 
PLD1 as stimulated by 1  g of GTP-loaded myrARF6 or 
myrARF6(N48I) was quantitated using the standard in vitro head-
group release assay. Averaged over three separate experiments, 
ARF6(N48I) demonstrated 7% of the activity of wt ARF6. Data are 
mean   one half the range of values from triplicate assays in one 
experiment representative of two/three experiments conducted 
using different protein preparations.
Figure 9. ARF6 interacts with PLD1 in stimulated PC12 cells. 
(A) PC12 cells cotransfected with pEGFP-PLD1 and pXS-ARF6 were 
incubated for 5 min in either Locke’s solution (R) or in 59 mM K
  
(S). Cells were subsequently stained with rabbit anti-ARF6 antibodies. 
Masks representing the regions of colocalization were generated by 
selecting the double-labeled pixels. Bars, 10  m. (B) PC12 cells 
expressing HA-ARF6 or HA-ARF6 mutants were incubated for 10 
min in either Locke’s solution (R) or in 59 mM K
  (S). Cells were 
scrapped and HA-tagged ARF6 proteins were immunoprecipitated. 
Samples were analyzed by electrophoresis and Western blotting 
using anti-ARF6 and anti-PLD1 antibodies. Similar results were 
obtained from three different cell preparations. 
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The granule-associated ARF6 is activated by ARNO at 
the plasma membrane upon PC12 cell stimulation
 
We previously compared the distribution of ARF6 in subcel-
lular fractions obtained from resting and stimulated chromaf-
fin cells and found that ARF6 apparently dissociates from
secretory granules and binds to the plasma membrane upon
cell stimulation (Caumont et al., 1998). Similarly, we found
here that overexpressed ARF6 proteins translocate from secre-
tory granule– to plasma membrane–containing fractions in
stimulated PC12 cells. Immunofluorescence and ultrastruc-
tural analysis confirm the association of ARF6 with secretory
granules and its relocalization at the plasma membrane upon
cell stimulation. A reasonable explanation is that the plasma
membrane location of ARF6 results from the docking of
secretory granules to sites of exocytosis. The observation that
ARF6 remains attached to the plasma membrane upon sub-
cellular fractionation of stimulated cells may reflect the direct
interaction of ARF6 with a plasma membrane–bound pro-
tein. The nucleotide exchange factor ARNO is an attractive
candidate to be the plasma membrane-bound partner of
ARF6 (Frank et al., 1998b). Indeed, ARNO colocalizes with
ARF6 in stimulated PC12 cells. Furthermore, we show here
that ARF6 is in its inactive GDP-bound state when associ-
ated with secretory granules, but becomes activated when re-
cruited to the plasma membrane. Conversely, overexpression
of ARNO increases GTP binding to ARF6 at the plasma
membrane whereas a catalytically inactive ARNO mutant
dramatically inhibits it. It is interesting to note that the con-
stitutively GDP-bound ARF6(T27N) could also be found as-
sociated to the plasma membrane in stimulated cells, suggest-
ing that GDP/GTP exchange is not required for the ARF6
association with plasma membrane. This observation is in
line with the idea that granules bring ARF6 to the plasma
membrane, making the protein transiently available for
ARNO upon docking at the exocytotic sites.
GDP-bound ARFs interact weakly with membranes
through hydrophobic interactions of the myristate and elec-
trostatic interactions of cationic residues with anionic lipids
(Antonny et al., 1997). Binding of GTP releases the NH
 
2
 
-
terminal helix from the protein core allowing a stronger in-
teraction with membranes through the NH
 
2
 
-terminal hy-
drophobic residues (Antonny et al., 1997). Using purified
chromaffin granules, we previously described that ARF6
coimmunoprecipitates with trimeric G protein 
 
 
 
 subunits
(Galas et al., 1997), suggesting that 
 
  
 
 subunits could serve
as anchors for GDP-bound ARF6 in the secretory granule
membrane. An appealing speculation is that the ARF6/
ARNO interaction is in some way under the control of the
granule-associated G protein 
 
  
 
 subunits. Thus, activation
of ARF6 would require the docking of granules to appropri-
ate ARNO-containing domains on the plasma membrane
and concomitant changes in the interactions of ARF6 with
 
  
 
 subunits. In favor of this idea, several recent reports de-
scribe 
 
  
 
 subunit regulation of the exocytotic fusion ma-
chinery, downstream of calcium entry, in secretory cells
(Pinxteren et al., 1998; Gensse et al., 2000) and as well as in
neuronal presynaptic terminals (Blackmer et al., 2001).
 
ARNO-induced ARF6 activation is critical for 
exocytosis in PC12 cells
 
We previously reported that a synthetic peptide, correspond-
ing in sequence to the myristoylated NH
 
2
 
-terminal domain
of ARF6 inhibited, in a dose-dependent manner, calcium-
evoked catecholamine secretion from permeabilized chro-
maffin cells (Galas et al., 1997; Caumont et al., 1998). More
recently, we described the presence of ARNO at the plasma
Figure 10. ARF6 regulates exocytosis by stimulating the plasma 
membrane-associated PLD1 in PC12 cells. (A) PC12 cells transfected 
with pXS-ARF6(N48I) in combination with the GH expression plasmid 
were stained with monoclonal anti-GH and rabbit polyclonal 
anti-ARF6 antibodies. Mask represents the regions of colocalization. 
Bar, 5  m. (B) PC12 cells expressing HA-ARF6(N48I) were labeled 
with [
32P]orthophosphate. Cells were then incubated in Locke 
(Resting) or stimulated with 59 mM K
  (Stimulated) and subsequently 
processed for subcellular fractionation. HA-ARF6(N48I) was 
immunoprecipitated from the cytosol (Cy), the plasma membrane 
(PM), and the secretory granules (Gr) and bound guanine nucleotides 
were analyzed by chromatography. (C) PC12 cells cotransfected 
with GH and the indicated ARF6 constructs were incubated for 10 
min in calcium-free Locke’s solution or in 59 mM K
 . The net 
K
 -evoked secretory response was obtained by subtracting the basal 
release from the release evoked by 59 mM K
 . Similar results were 
obtained in two independent experiments performed with different 
cell cultures. 
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membrane in chromaffin cells and demonstrated that over-
expression of WT ARNO enhanced secretagogue-evoked se-
cretion from PC12 cells whereas the catalytically inactive
ARNO(E156K) mutant inhibited it (Caumont et al., 2000).
These results suggested, but did not prove, that an ARNO-
regulated ARF6 plays an important role in exocytosis. In-
deed, ARNO is exchange factor for both ARF1 and ARF6,
and both ARFs can be detected at the plasma membrane in
chromaffin cells (Galas et al., 1997). Moreover, although
ARF peptides have been described to block ARF activities in
various cellular processes (Barr and Huttner, 1996; Le
Stunff et al., 2000; Mukherjee et al., 2000), their specificity
has also been questioned (Fensome et al., 1994). Using di-
rect means, we demonstrate here for the first time that ARF6
is the sole member of the ARF family involved in the molec-
ular pathway underlying calcium-regulated exocytosis. Al-
though the involvement of ARF6 in peripheral vesicle traf-
ficking has been reported previously in various cell types,
this specific requirement for ARF6 in secretion is surprising
and may be linked to its granular location and its specific ac-
tivation at granule targeting sites.
 
PLD1 is a major downstream effector of ARF6 
in the exocytotic process
 
One of the proposed functions of ARF6 is to mediate actin
rearrangements (Chavrier and Goud, 1999). Activation of
ARF6 can also lead to significant changes in the lipid
composition of specific membrane domains, as the pro-
tein is known to directly activate two lipid-modifying en-
zymes, PLD and phosphatidylinositol-4-phosphate 5-kinase
(Honda et al., 1999). Thus, activation of ARF6 at the exocy-
totic sites may provide a mechanism whereby secretory cells
can engineer a localized remodeling of the actin cytoskeleton
with phospholipid modifications, so that the fusion machin-
ery can negotiate the exocytotic event. Using rhodamine-
conjugated phalloidin to visualize actin filaments, we have
investigated whether ARF6 mutants affect the depolymeriza-
tion of cortical actin observed in stimulated cells. However,
we could not correlate the strong inhibition of secretion in-
duced by ARF6(T27N) to a stabilization of the cortical ac-
tin barrier (unpublished data). Accordingly, we found that
the secretagogue-dependent movement of secretory gran-
ules to the cell periphery was similar in control and in
ARF6(T27N)-expressing cells. Thus, ARF6 is probably not
involved in the partial depolymerization of the cortical actin
cytoskeleton that enables recruitment of the reserve pool of
secretory granules to the plasma membrane. This finding is
in line with the idea that ARF6 is activated after docking of
secretory granules to the sites of exocytosis. Whether ARF6
mediates some other subtle modifications of the actin cyto-
skeleton functionally required in late stages of the exocytotic
machinery cannot be excluded and will be an interesting fu-
ture issue.
We recently demonstrated that PLD1 constitutes a critical
factor for regulated exocytosis in neuroendocrine cells (Vi-
tale et al., 2001) and neurons (Humeau et al., 2001), operat-
ing subsequent to the cytoskeletal-mediated recruitment of
secretory granules to exocytotic sites (Vitale et al., 2001). To
directly probe the idea that ARF6 is the upstream activator
of the plasma membrane-bound PLD1 in the exocytotic
pathway, we generated a novel ARF6(N48I) mutant that
specifically lost its ability to stimulate PLD1, based on anal-
ogy with a similar ARF1 mutant defective in PLD activation
but still able to activate phosphatidylinositol-4-phosphate
5-kinase (Jones et al., 1999; Skippen et al., 2002). Expres-
sion of ARF6(N48I) inhibited secretagogue-evoked GH se-
cretion to an extent similar to the constitutively inactive
ARF6(T27N), suggesting that the stimulation of PLD1 is
the major function ARF6 undertakes in regulated exocytosis.
Accordingly, ARF6 interacts directly with PLD1 at the
plasma membrane in stimulated cells. Our previous observa-
tion that the introduction of specific anti-ARNO antibodies
into permeabilized chromaffin cells inhibited in a similar
manner catecholamine secretion and PLD activation (Cau-
mont et al., 2000) further corroborates the ARNO–ARF6–
PLD1 cascade in the exocytotic process.
How does PLD1 relate to our current understanding of
the protein machinery responsible for regulated exocytosis?
PLD1 catalyzes the hydrolysis of phosphatidylcholine to
produce membrane-localized phosphatidic acid (PA). An ex-
citing speculation relates to the changes in the lipid bilayer
properties created by the activation of PLD. PA is a cone-
shaped lipid which promotes membrane curvature and the
formation of hemifusion intermediates required for the fu-
sion of two membranes (Monck and Fernandez, 1994).
Thus, the predicted effect of a local elevation of PA due to
the activation of PLD1 at exocytotic sites would be to pro-
mote membrane bending, particularly in the presence of cal-
cium, thereby facilitating membrane breakdown and subse-
quent formation of the exocytotic fusion pore. Accordingly,
data obtained by amperometry on isolated chromaffin cells
suggest that PLD1 affects the kinetics of the initial fusion
event and/or the rate of the fusion pore opening (Vitale et
al., 2001). Similarly, electrophysiological analysis suggest
that the role played by PLD1 in neurotransmission is related
to the fusogenic status of the presynaptic release sites (Hu-
meau et al., 2001). Hence, the ARF6–PLD1 complex may
provide to the protein scaffold pulling membrane together
the lipid counterparts required to open and/or expand the
fusion pore.
 
Materials and methods
 
Antibodies, DNA constructs, and proteins
 
The following antibodies were used: rabbit polyclonal anti-ARF6 antibod-
ies, provided by J. Donaldson (National Institutes of Health, Bethesda,
MD) (Radhakrishna and Donaldson, 1997); rabbit polyclonal anti–human
GH antibodies, provided by Dr. A.F. Parlow (Los Angeles County Harbor–
UCLA Medical Center, Torrance, CA) and the National Institute of Diabe-
tes and Digestive and Kidney Diseases National Hormone and Pituitary
Program; polyclonal anti-Rab5 antibodies, provided by M. Zerial (Max
Planck Institute for Molecular Cell Biology and Genetics, Dresden, Ger-
many); monoclonal anti–human GH antibodies (Nichols Institute); mono-
clonal anti–SNAP-25 antibodies (Sternberger Monoclonals, Inc.); mono-
clonal anti-HA antibodies (BabCO); monoclonal anti-myc antibodies
(Novocastra Laboratories). Cy2-anti–mouse, Cy3-anti–rabbit, and Cy5-
anti–mouse were obtained from Amersham Biosciences. pECFP-Golgi was
purchased from Stratagene.
The ARF and ARNO constructs, provided by J.E. Casanova (Univer-
sity of Virginia Health System, Charlottesville, VA), were described pre-
viously (Frank et al., 1998a; Morinaga et al., 2001). pXS-ARF6(N48I)
and pXS-ARF6(N48I-Q67L) were generated by site-directed mutagene-
sis with a Quickchange mutagenesis kit from Stratagene (Vitale et al.,
2000a).
Recombinant myrARF6 and myrARF6(N48I) were expressed and puri- 
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fied as described previously (Vitale et al., 2000b). Recombinant ARNO
was expressed as described (Pacheco-Rodriguez et al., 1998).
 
Culture, transfection, and assay of GH release from PC12 cells
 
PC12 cells were grown in DME supplemented with glucose (4,500 mg/L)
and containing 30 mM NaHCO
 
3
 
, 5% fetal bovine serum, 10% horse serum
and 100 U/ml penicillin/streptomycin. Mammalian expression vectors
were introduced into PC12 cells together with the GH plasmid pXGH5
(6-well dishes, 80% confluent, 0.4 
 
 
 
g/well of each plasmid) using Gene-
Porter (Gene Therapy Systems) according to the manufacturer’s instruc-
tion. After 5 h of incubation at 37
 
 C, 2 ml of culture medium containing fe-
tal bovine serum, horse serum, and antibiotics was added.
GH release experiments were performed 48 h after transfection. PC12
cells were washed twice with Locke’s solution and then incubated for 10
min with calcium-free Locke’s solution (basal release) or stimulated with
an elevated K
  solution (Locke’s containing 59 mM KCl and 85 mM NaCl).
The supernatant was collected and the cells harvested by scraping in 10
mM phosphate buffered saline. The amounts of GH secreted into the me-
dium and retained in the cells were measured using a radioimmunoassay
kit (Nichols Institute). The amount of GH secretion is expressed as a per-
centage of total GH present in the cells before stimulation.
Distribution and nucleotide status of ARF6 
in PC12 cell subcellular fractions
PC12 cells grown in 100-mm plates were transfected with various plasmids
(for each 10  g per plate) using GenePorter. 36 h after transfection, cells
were incubated in 2 ml/plate phosphate- and serum-free DME medium,
supplemented with 25 mM Hepes, pH 7.2, 2 mM pyruvate and 175  ci of
[
32P]orthophosphate for 24 h. PC12 cells were washed twice with Locke’s
solution and then incubated for 15 min with Locke’s solution (basal release)
or stimulated with an elevated K
  solution. Medium was removed and cells
immediately scrapped in 1 ml of sucrose 0.32 M (20 mM Tris, pH 8.0). Cells
were broken in a Dounce homogenizer and centrifuged at 800 g for 15 min.
The supernatant was further centrifuged at 20,000 g for 20 min. The result-
ing supernatant was further centrifuged for 60 min at 100,000 g to obtain the
cytosol (supernatant) and microsomes (pellet enriched in endosomes). The
20,000 g pellet containing the crude membrane fraction was resuspended
in sucrose 0.32 M (20 mM Tris, pH 8.0), layered on a cushion sucrose den-
sity gradient (sucrose 1–1.6 M, 20 mM Tris, pH 8.0) and centrifuged for 90
min at 100,000 g to separate the plasma membrane from secretory granules
(Caumont et al., 2000). The upper fractions containing SNAP-25 (plasma
membrane marker) and the pellet containing GH and dopamine– -hydrox-
ylase (secretory granule markers) were collected and resuspended in buffer
A (20 mM Tris, pH 8.0, 100 mM NaCl, 1 mM MgCl2, 1% Triton X-100,
0.05% cholate, 0.005% SDS, 1 mM dithiothreitol, 1 mM phenylmethylsul-
fonyl fluoride, 5  g/ml aprotinin, 5  g/ml leupeptin, 1 mM NaF, 1 mM van-
adate, 0.32 M sucrose). To immunoprecipitate ARF6 proteins, 5  l anti-HA
antiserum and 10  l of protein A Sepharose beads were added to 500  l of
cytosol, plasma membrane, and secretory granule fractions. Immunoprecip-
itation was performed for 3 h at 4 C, followed by extensive washing of the
protein A beads with ice cold buffer B (50 mM Hepes, pH 7.4, 0.5 M NaCl,
5 mM MgCl2, 0.1% Triton X-100, 0.05% cholate, 0.005% SDS). Elution was
carried out in Laemmli buffer for samples subjected to SDS-PAGE and in 40
 l of 2 M formic acid (heated at 70 C for 3 min) for samples analyzed by
thin layer chromatography (Vitale et al., 2000b).
Immunoblotting, immunofluorescence, 
and confocal microscopy
One-dimensional SDS gel electrophoresis was performed on 10% acryl-
amide gels in Tris-Glycine buffer. The proteins were transferred to nitrocel-
lulose sheets at a constant current of 120 mA for 1 h. Blots were developed
using secondary antibodies coupled to horseradish peroxidase (Amersham
Biosciences) and the immunoreactive bands detected using the ECL system
(Amersham Biosciences).
For immunocytochemistry, PC12 cells grown on poly-D-lysine–coated
glass coverslips were maintained in Locke’s solution or stimulated with el-
evated K
 . The cells were then fixed for 20 min in 4% paraformaldehyde
in 0.12 M sodium/phosphate, pH 7.0, and for a further 10 min in fixative
containing 0.1% Triton X-100. Immunostaining was performed as de-
scribed previously (Vitale et al., 2001) and stained cells were visualized
using a Zeiss confocal microscope LSM 510.
Preembedding immunoelectron microscopy
PC12 cells transfected with pXS-ARF6 were stimulated with 59 mM K
  and
fixed for 45 min with 3% paraformaldehyde and 0.2% glutaraldehyde in
0.1 M sodium/phosphate, pH 7.2. Immunostaining was performed using
anti-HA antibodies according to the immunogold silver labeling procedure
described by Yi et al. (2001).
Molecular characterization of myrARF6(N48I)
Time-course GTP S binding assays were performed with 0.5  g of
myrARF6 or myrARF6(N48I) essentially as described (Vitale et al., 1997).
In the presence or absence of GIT1, provided by R.T. Premont (Duke Uni-
versity Medical Center, Durham, NC), GTPase activity of 0.5  g of
myrARF6 or myrARF6(N48I) was measured for 10 min at 30 C as de-
scribed previously (Vitale et al., 2000b). ARF stimulation of cholera toxin-
catalyzed ADP-ribosylagmatine formation was performed with 0.5  g of
myrARF6 or myrARF6(N48I) as described (Vitale et al., 1997). PLD activity
assays were carried out using the in vitro head-group release assay for a
30-min time period as previously described (Zhang et al., 1999b). Recom-
binant WT and mutant ARF6 were loaded using 50  M GTP S as previ-
ously described (Frohman et al., 2000) and were used at 0.5  M (1  g/
100  l reaction). Assay blanks were subtracted. The source of PLD1 pro-
tein was a tet-regulated stable CHO cell line that had been induced for
24 h in a 35-mm dish before harvesting and sonication. The sonicated ly-
sate was centrifuged for 30 min at 4 C and 20,000 g to pellet the PLD1,
and the supernatant containing the Rho and ARF small GTP proteins re-
moved. 100  l of PBS containing protease inhibitors was added to the pel-
let which was then sonicated briefly to evenly resuspend it. 1  l of the re-
sulting PLD1 source was used for each assay sample.
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